What’s Going on with Biogen Inc.?
Biogen Inc. (BIIB) has just released results from its two-year natalizumab Phase 3b NOVA study comparing the efficacy of the already approved every four-week (Q4W) dose with the efficacy of every six-week dosing. Pre-market today, BIIB stock held fairly steady, trading at $326.73 a share, which matches last Friday's (July 30) closing price.
What Does This Mean for BIIB?
Results from the Phase 3b NOVA study demonstrated that every six-week (Q6W) natalizumab IV administration offered “a high level of efficacy in controlling MS disease activity in patients who switched from the approved every four-week dosing regimen.”
In terms of endpoints, according to a Biogen Inc. news release, “There were no statistically significant or clinically meaningful differences in secondary endpoints at week 72 between the Q4W and Q6W treatment arms, and disease activity was well-controlled in both arms.”
Biogen Chief Medical Officer Maha Radhakrishnan pointed out that this Phase 3b NOVA study "provides the first prospective, randomized efficacy data of every six-week dosing with natalizumab, building on its well-established clinical profile and the real-world findings.”
BIIB has a Fundamental Rank of 71. Find out what this means to you and get the rest of the rankings on BIIB!
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
